Andrew Benjamin Nixon, PhD

Associate Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Melosky, B, Reardon, DA, Nixon, AB, Subramanian, J, Bair, AH, and Jacobs, I. "Bevacizumab biosimilars: scientific justification for extrapolation of indications." Future Oncology (London, England) 14, no. 24 (October 2018): 2507-2520.

PMID
29690784
Full Text

Liu, Y, Starr, MD, Brady, JC, Rushing, C, Pang, H, Adams, B, Alvarez, D, Theuer, CP, Hurwitz, HI, and Nixon, AB. "Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105." Molecular Cancer Therapeutics 17, no. 10 (October 2018): 2248-2256.

PMID
29997150
Full Text

Choueiri, TK, Michaelson, MD, Posadas, EM, Sonpavde, GP, McDermott, DF, Nixon, AB, Liu, Y, Yuan, Z, Seon, BK, Walsh, M, Jivani, MA, Adams, BJ, and Theuer, CP. "An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma." The Oncologist (September 6, 2018).

PMID
30190302
Full Text

Vlahovic, G, Meadows, KL, Hatch, AJ, Jia, J, Nixon, AB, Uronis, HE, Morse, MA, Selim, MA, Crawford, J, Riedel, RF, Zafar, SY, Howard, LA, O'Neill, M, Meadows, JJ, Haley, ST, Arrowood, CC, Rushing, C, Pang, H, and Hurwitz, HI. "A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer." The Oncologist 23, no. 7 (July 2018): 782-790.

PMID
29572245
Full Text

Secord, AA, Previs, RA, and Nixon, AB. "Cabozantinib in ovarian clear cell cancers: UnMET expectations." Gynecologic Oncology 150, no. 1 (July 2018): 1-2.

PMID
29935857
Full Text

Seligmann, JF, Hatch, AJ, Richman, SD, Elliott, F, Jacobs, B, Brown, S, Hurwitz, H, Barrett, JH, Quirk, P, Nixon, AB, and Seymour, MT. "Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer." Jama Oncology 4, no. 4 (April 1, 2018): 564-568. (Academic Article)

Full Text

Seligmann, JF, Hatch, AJ, Richman, SD, Elliott, F, Jacobs, B, Brown, S, Hurwitz, H, Barrett, JH, Quirke, P, Nixon, AB, and Seymour, MT. "Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer." Jama Oncology 4, no. 4 (April 2018): 564-568.

PMID
29075780
Full Text

Ronald, J, Nixon, AB, Marin, D, Gupta, RT, Janas, G, Chen, W, Suhocki, PV, Pabon-Ramos, W, Sopko, DR, Starr, MD, Brady, JC, Hurwitz, HI, and Kim, CY. "Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma." Radiology 285, no. 1 (October 2017): 311-318.

PMID
28787261
Full Text

Corradetti, M, Hatch, A, Torok, J, Xanthopoulos, E, Rushing, C, Calaway, J, Jones, G, Nixon, A, and Kelsey, C. "Dynamic Changes in Cell-Free DNA During Chemoradiation for Non–small Cell Lung Cancer." October 2017.

Full Text

Thompson, EM, Keir, ST, Venkatraman, T, Lascola, C, Yeom, KW, Nixon, AB, Liu, Y, Picard, D, Remke, M, Bigner, DD, Ramaswamy, V, and Taylor, MD. "The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival." Neuro Oncology 19, no. 9 (September 2017): 1217-1227.

PMID
28379574
Full Text

Pages